Search - tctmd.com

Displaying 181 - 200 of 386

Sort: Relevancy | Date

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

L.A. McKeown

May 03, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Featured Fellow

Eric Secemsky, MD, MSc

Yael L. Maxwell

March 21, 2017

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Todd Neale

March 10, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

Presentation TCT 2016

Deciding on the Duration of DAPT

Presenter: George D. Dangas, Debabrata Mukherjee, Neal S. Kleiman

November 01, 2016

Presentation TCT 2016

Case Presentation: Difficult DAPT Duration Decision After PCI

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Marcelo Bettinotti

October 31, 2016

Presentation TCT 2016

Duration of DAPT Therapy With Contemporary DES (Including BVS)

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Gustavo A Samaja

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Presenter: John A. Bittl, Daniel I. Simon, Eric Van Belle

October 30, 2016

Presentation TCT 2016

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Presenter: John A. Bittl, Daniel I. Simon, Tullio Palmerini

October 30, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation TCT 2016

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Presenter: John A. Bittl, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Presenter: John A. Bittl, Daniel I. Simon, Robert W. Yeh

October 30, 2016

Presentation TCT 2016

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Presenter: John A. Bittl, Daniel I. Simon, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Advertisement

Use of DAPT Score Following PCI Validated in PRODIGY Study

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Eric Secemsky, MD, MSc

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Deciding on the Duration of DAPT

Case Presentation: Difficult DAPT Duration Decision After PCI

Duration of DAPT Therapy With Contemporary DES (Including BVS)

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content